Lasa Supergenerics Ltd

Lasa Supergenerics Ltd has submitted its Annual Report for the financial year ended March 31, 2026, to the stock exchanges. The company announced that its Eleventh (11th) Annual General Meeting (AGM) is scheduled to be held on Wednesday, September 30, 2026, at 09:30 AM via Video Conferencing or Other Audio Visual Means. The Annual Report and the Notice for the AGM are being sent to members electronically and are also available on the company's website. September 23, 2026, has been fixed as the cut-off date for e-voting. Additionally, the Register of Members and Share Transfer Books will remain closed from September 23, 2026, to September 29, 2026 (both days inclusive).

Lasa Supergenerics Ltd has announced the details for its Eleventh Annual General Meeting (AGM), scheduled for Wednesday, September 30, 2026, at 9:30 AM IST. The meeting will be conducted via Video Conferencing (VC) / Other Audio-Visual means (OAVM). Key agenda items include the adoption of the Directors' Report, Corporate Governance Report, Management Discussion and Analysis Report for the financial year ended March 31, 2026. The company also approved the appointment of Shravan A. Gupta & Associates as scrutinizers and the re-appointment of Mr. Omkar Herlekar as a Director liable to retire by rotation. The Register of Members and Share Transfer Books will be closed from September 23 to September 29, 2026.

Lasa Supergenerics Ltd announced the outcome of its board meeting, detailing the upcoming Eleventh Annual General Meeting (AGM) scheduled for September 30, 2026. The meeting will be conducted via Video Conferencing (VC) / Other Audio-Visual means (OAVM). The board also approved the Director's Report, Corporate Governance Report, and Management Discussion and Analysis Report for the financial year ended March 31, 2026. Additionally, a scrutinizer was appointed for the AGM, and the Register of Members and Share Transfer Books will be closed from September 23 to September 29, 2026. The re-appointment of Director Mr. Omkar Herlekar was also approved.

Lasa Supergenerics Ltd announced the appointment of Mr. Janardan Kamlu Savala as an Additional Director in the capacity of Executive Director. This appointment is subject to the approval of the company's members at the upcoming General Meeting or via Postal Ballot. Mr. Savala brings experience in business operations, commercial practices, and banking-related processes. His profile, including his date of birth (15/05/1994), nationality (Indian), and qualifications (Under Graduate), was enclosed as per SEBI regulations. The board meeting where this was approved commenced at 11:00 a.m. and concluded at 1:00 p.m. on August 26, 2026.

Lasa Supergenerics Limited has submitted its integrated filing for the quarter ended June 30, 2026. The Board of Directors approved the unaudited financial results and the Limited Review Report from the Statutory Auditor. The company reported a net loss after tax for the quarter. The filing also addresses the impact of a fire incident in the previous year, ongoing operational disruptions, and the company's exploration of alternative manufacturing arrangements. The company confirmed no defaults on loans or debt securities.

Lasa Supergenerics Ltd has announced that its Board of Directors will convene on August 14, 2026. The primary agenda items include the consideration and approval of the unaudited financial results for the quarter ended June 30, 2026. Additionally, the board will discuss any other matters with the Chairperson's permission. In line with SEBI regulations, the trading window will remain closed until 48 hours after the declaration of these financial results. The company has also made this information available on its website and the BSE and NSE websites.

Lasa Supergenerics Ltd has announced the closure of its trading window for designated employees and their immediate relatives. This closure is effective from July 01, 2026, and will remain in effect until 48 hours after the declaration of the Unaudited Financial Results for the quarter ended June 30, 2026. This measure is in compliance with the company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, as per SEBI (Prohibition of Insider Trading) Regulations, 2015.

Lasa Supergenerics Ltd has announced its audited financial results for the quarter and year ended March 31, 2026. The Board of Directors approved the results on May 29, 2026, following a review by the audit committee. Revenue from operations for the year ended March 31, 2026, stood at ₹2,514.07 Lakhs. The statutory auditors issued an audit report with a modified opinion. A fire incident at the company's factory on May 18, 2025, resulted in significant damage.

Lasa Supergenerics Ltd. disclosed its related party transactions as of March 31, 2026, in compliance with Regulation 23(9) of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015. The transactions include remuneration to directors, sitting fees to independent directors, remuneration to the company secretary and CFO, and donations given. The total value of these transactions amounts to ₹35.36.

Lasa Supergenerics Ltd's board approved the audited financial results for the quarter and year ended March 31, 2026. Revenue from operations for the year ended March 31, 2026, stood at ₹2,514.07 lakhs. The company reported a net loss after tax of ₹2,211.66 lakhs. The auditor's report for the quarter ended March 31, 2026, has a modified opinion. A fire incident at the company's factory on May 18, 2025, resulted in significant damage and operational disruption, with uninsured losses recognized as exceptional items.